Table 2.
EXO_GOOD_UP | EXO_GOOD_DOWN | ||||||
---|---|---|---|---|---|---|---|
KEGG Pathway | p-Value | #Genes | #miRNAs | KEGG Pathway | p-Value | #Genes | #miRNAs |
Proteoglycans in cancer | 1.50 × 10−9 | 56 | 3 | Prion diseases | 0 | 11 | 4 |
Viral carcinogenesis | 8.92 × 10−9 | 59 | 6 | Fatty acid biosynthesis | 0 | 5 | 8 |
Glioma | 2.52 × 10−6 | 30 | 6 | Steroid biosynthesis | 0 | 9 | 9 |
Chronic myeloid leukemia | 5.74 × 10−6 | 34 | 4 | Fatty acid metabolism | 0 | 19 | 9 |
MicroRNAs in cancer | 1.56 × 10−4 | 26 | 4 | Viral carcinogenesis | 0 | 119 | 11 |
Non-small cell lung cancer | 3.37 × 10−4 | 21 | 2 | Hippo signaling pathway | 0 | 91 | 15 |
Renal cell carcinoma | 4.01 × 10−3 | 23 | 3 | ECM-receptor interaction | 0 | 39 | 17 |
Prostate cancer | 4.31 × 10−3 | 33 | 3 | Proteoglycans in cancer | 0 | 132 | 17 |
Adherens junction | 4.44 × 10−3 | 19 | 4 | Cell cycle | 3.33 × 10−16 | 79 | 10 |
Central carbon metabolism in cancer | 4.74 × 10−3 | 19 | 3 | Adherens junction | 8.88 × 10−16 | 58 | 14 |
Other types of O-glycan biosynthesis | 5.85 × 10−3 | 9 | 2 | Lysine degradation | 2.89 × 10−15 | 26 | 11 |
Pancreatic cancer | 7.21 × 10−3 | 27 | 3 | Pathways in cancer | 1.69 × 10−13 | 197 | 12 |
Lysine degradation | 9.84 × 10−3 | 12 | 3 | Hepatitis B | 8.91 × 10−12 | 77 | 9 |
TGF-beta signaling pathway | 1.04 × 10−2 | 25 | 3 | Glioma | 1.70 × 10−10 | 43 | 14 |
FoxO signaling pathway | 1.10 × 10−2 | 38 | 2 | TGF-beta signaling pathway | 1.13 × 10−9 | 56 | 12 |